Restricting systematic prostate biopsy cores to the side of a unilateral magnetic resonance imaging lesion achieves detection rates of clinically significant prostate cancer comparable to bilateral full sampling, according to findings from a retrospective paired cohort study. The investigation evaluated whether omitting contralateral systematic sampling compromises diagnostic accuracy when combined with cognitive magnetic resonance imaging-targeted biopsy in biopsy-naïve men.
The study reviewed medical records of biopsy-naïve men evaluated at a single center between June 2022 and June 2025. Eligible participants presented with a solitary unilateral lesion identified on multiparametric magnetic resonance imaging assigned a Prostate Imaging Reporting and Data System score of 3 or higher. All enrolled patients had undergone both cognitive targeted sampling and full systematic tissue acquisition during the same intervention.
The biopsy protocol comprised cognitive magnetic resonance imaging-targeted acquisition of 3 to 4 tissue cores alongside a standard 10- to 12-core systematic biopsy. Researchers defined ipsilateral systematic biopsy as the subset of systematic cores obtained exclusively from the identical prostatic lobe housing the index imaging lesion. Clinically significant prostate cancer was defined as International Society of Urological Pathology grade group 2 or higher, and discordant diagnostic pairs were evaluated using McNemar’s test.
Among the 86 patients analyzed in the cohort, prostate malignancy was identified overall in 69.8 percent of cases. Detection rates for clinically significant disease showed no statistically significant difference between the combined full systematic approach and the ipsilateral strategy, yielding 33.7 percent and 32.6 percent, respectively, with a p-value of 1.00.
Evaluating discordant pairs demonstrated that full systematic sampling detected only one additional clinically significant prostate cancer beyond the ipsilateral approach, representing a miss rate of 3.4 percent and an added detection rate of 1.2 percent. In contrast, the full bilateral systematic approach detected significantly more clinically insignificant tumors, identifying low-grade disease in 36.0 percent of cases compared to 29.1 percent with ipsilateral sampling, corresponding to a p-value of 0.031 and a 19.4 percent miss rate for insignificant disease.
The investigators concluded that confining systematic biopsy sampling to the ipsilateral side alongside cognitive targeted biopsy preserves the identification of clinically significant tumors while reducing the detection of indolent disease in men with unilateral imaging lesions. The authors noted that further prospective studies are needed to confirm these findings.
Subject of Research: Prostate cancer detection using ipsilateral versus full systematic biopsy combined with cognitive MRI targeting
Article Title: Ipsilateral versus full systematic sampling combined with cognitive MRI-targeted biopsy for prostate cancer detection in biopsy-naïve men with unilateral mpMRI lesions: a retrospective paired cohort study
Article References: Tsakaldimis, G., Diamantidis, D., Smyrlis, N., Lailisidis, S., Kafalis, C., Foutzitzi, K., Matthaios, D., Giannakopoulos, S., & Kalaitzis, C. (2026). Ipsilateral versus full systematic sampling combined with cognitive MRI-targeted biopsy for prostate cancer detection in biopsy-naïve men with unilateral mpMRI lesions: a retrospective paired cohort study. BMC Urology. https://doi.org/10.1186/s12894-026-02405-w
Image Credits: AI Generated
DOI: 10.1186/s12894-026-02405-w
Keywords: prostate cancer, multiparametric MRI, systematic biopsy, cognitive targeted biopsy, ipsilateral systematic biopsy, clinically significant prostate cancer, clinically insignificant prostate cancer, PI-RADS, ISUP grade group, biopsy-naïve patients, unilateral mpMRI lesions, urology, retrospective cohort study, McNemar test, paired comparison, diagnostic accuracy
News Source: Nathaniel Bowman. (November 10, 2026). Ipsilateral Biopsy Matches Full Systematic Sampling for Clinically Significant Prostate Cancer. Scienmag.



